Methylphenidate and Central Precocious Puberty: A Probable Side Effect Among Seven Children With ADHD
Ayca Torel Ergur 2, Hesna Gül 1*, Ahmet Gül 3
1Gulhane Research and Training Hospital, 2Ufuk University, Child Endocrinology, 3Ufuk University, Psychiatry
Received: January 10, 2018; Revised: February 17, 2018; Accepted: March 7, 2018; Published online: March 7, 2018.
© The Korean College of Neuropsychopharmacology. All rights reserved.

Objectives: MPH is the most preferred drug for treatment of ADHD. Here, we aimed to discuss the possible effects and mechanisms of methylphenidate (MPH) on precocious puberty via a case series with seven children who had normal body mass index( BMI).
Methods: In this case series we evaluated seven children with ADHD, who had received MPH for at least 6 months (0.5 mg/kg/dose three times a day, maximum 60 mg) and admitted to Pediatric Endocrinology Department with precocious puberty (PP) symptoms.
Results: The mean age was 8.16 years. Basal hormonal levels (LH, FSH, estrogen/testosterone) were within normal range. Results of LHRH stimulation tests demonstrated central pubertal responses.
Conclusion: Glutamine, dopamine, and noradrenaline are most important excitatory neurotransmitters that have a role at the beginning of puberty. The effect of MPH, cumulating dopamine and noradrenaline in the synaptic gap could be associated with the acceleration of puberty with the excitatory effect of dopamine’s GnRH release, excitatory effect of noradrenaline’s GnRH release and the disappearance of GnRH-R expression suppressor effect on prolactin’s HH region with prolactin disinhibitory effect.
Key Words: Attention Deficit Disorder and Hyperactivity Disorder, Methylphenidate, Central precocious puberty
Keywords: Attention Deficit Hyperactivity Disorder, Central precocious puberty, Methylphenidate